Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Ginsberg

Showing results (561-570 of 607) with videos related to

Pageof 61
Sort By:
Clinical Immunology (Orlando, Fla.)|January 13, 1999
Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trialJ D Boyer, M A Chattergoon, K E Ugen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 17, 2023
Clinical outcomes of stereotactic body radiation therapy for malignant pleural mesotheliomaJacob Y Shin, Michael Offin, Charles B Simone, et al.
Lung Cancer (Amsterdam, Netherlands)|September 8, 2014
Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferaseMarjorie G Zauderer, Alex Drilon, Kyuichi Kadota, et al.
Plos Biology|January 28, 2021
Why Lyme disease is common in the northern US, but rare in the south: The roles of host choice, host-seeking behavior, and tick densityHoward S Ginsberg, Graham J Hickling, Russell L Burke, et al.
Plos Biology|September 8, 2021
Correction: Why Lyme disease is common in the northern US, but rare in the south: The roles of host choice, host-seeking behavior, and tick densityHoward S Ginsberg, Graham J Hickling, Russell L Burke, et al.
JTO Clinical and Research Reports|July 21, 2025
A Phase II Study of Cabozantinib in Patients With <i>MET</i>-Altered Lung CancersGuilherme Harada, Fernando C Santini, Clare J Wilhelm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural MesotheliomaAndreas Rimner, Marjorie G Zauderer, Daniel R Gomez, et al.
Cancer Discovery|September 22, 2020
Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 BlockadeKathryn C Arbour, Anh Tuan Luu, Jia Luo, et al.
JAMA|June 8, 2006
Sunitinib in patients with metastatic renal cell carcinomaRobert J Motzer, Brian I Rini, Ronald M Bukowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2024
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung CancerNoura J Choudhury, W Victoria Lai, Alex Makhnin, et al.
Pageof 61

Showing results (561-570 of 607) with videos related to

Sort By:
Pageof 61
Clinical Immunology (Orlando, Fla.)|January 13, 1999
Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trialJ D Boyer, M A Chattergoon, K E Ugen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 17, 2023
Clinical outcomes of stereotactic body radiation therapy for malignant pleural mesotheliomaJacob Y Shin, Michael Offin, Charles B Simone, et al.
Lung Cancer (Amsterdam, Netherlands)|September 8, 2014
Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferaseMarjorie G Zauderer, Alex Drilon, Kyuichi Kadota, et al.
Plos Biology|January 28, 2021
Why Lyme disease is common in the northern US, but rare in the south: The roles of host choice, host-seeking behavior, and tick densityHoward S Ginsberg, Graham J Hickling, Russell L Burke, et al.
Plos Biology|September 8, 2021
Correction: Why Lyme disease is common in the northern US, but rare in the south: The roles of host choice, host-seeking behavior, and tick densityHoward S Ginsberg, Graham J Hickling, Russell L Burke, et al.
JTO Clinical and Research Reports|July 21, 2025
A Phase II Study of Cabozantinib in Patients With <i>MET</i>-Altered Lung CancersGuilherme Harada, Fernando C Santini, Clare J Wilhelm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2016
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural MesotheliomaAndreas Rimner, Marjorie G Zauderer, Daniel R Gomez, et al.
Cancer Discovery|September 22, 2020
Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 BlockadeKathryn C Arbour, Anh Tuan Luu, Jia Luo, et al.
JAMA|June 8, 2006
Sunitinib in patients with metastatic renal cell carcinomaRobert J Motzer, Brian I Rini, Ronald M Bukowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2024
A Phase I/II Study of Valemetostat (DS-3201b), an EZH1/2 Inhibitor, in Combination with Irinotecan in Patients with Recurrent Small-Cell Lung CancerNoura J Choudhury, W Victoria Lai, Alex Makhnin, et al.
Pageof 61